A Meaningful Shift In FDA's Biosimilarity Analysis
The U.S. Food and Drug Administration's October draft guidance on biosimilar biologic license applications signals a meaningful shift in how the agency will analyze biosimilarity and interchangeability.[1]...To view the full article, register now.
Already a subscriber? Click here to view full article